Drug Profile

Latanoprost - Novartis

Latest Information Update: 12 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kedalion Therapeutics
Developer Novartis
Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
Mechanism of Action Prostaglandin F2 alpha agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Glaucoma

Most Recent Events

28 Oct 2020 No recent reports of development identified for phase-I development in Glaucoma in USA (Topical)
28 Feb 2019 Kedalion Therapeutics plans a phase II trial for Glaucoma in 2019
01 Jan 2015 US FDA confirms 505(b) regulatory pathway for AcuStream combined with latanoprost

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com